Current and emerging therapy for primary pulmonary hypertension

Annals of Pharmacotherapy

Volumn 36, Issue 9, 2002, Pages 1414-1423

  Pass, Steven E ^a   Dusing, Michelle L ^a   Perez, Annette ^a   Paquette Lamontagne, Nicolas ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Beraprost; Bosentan; Epoprostenol; Iloprost; Pulmonary hypertension; Treprostinil

Indexed keywords

ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; ILOPROST; NIFEDIPINE; PROSTACYCLIN; UNCLASSIFIED DRUG; UNIPROST; VASODILATOR AGENT; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE;

ANTICOAGULATION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DATA BASE; DIAGNOSTIC TEST; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENDER; HUMAN; INCIDENCE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEDICAL DECISION MAKING; MEDLINE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; PULMONARY HYPERTENSION; SEX RATIO; SURVIVAL TIME; SYMPTOM; THROMBOSIS; TREATMENT PLANNING; VASOCONSTRICTION; VASODILATATION; PATHOPHYSIOLOGY; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; VASODILATOR AGENTS;

EID: 0036707922     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C015     Document Type: Article

References (58)

1. ACCP consensus statement: Primary pulmonary hypertension
2. Primary pulmonary hypertension
3. Primary pulmonary hypertension: Update on pathogenesis and novel therapies
4. Primary pulmonary hypertension
5. Primary pulmonary hypertension. A national prospective study
6. Current management of primary pulmonary hypertension
7. Primary pulmonary hypertension associated with the use of fenfluramine derivatives
8. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
9. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry
10. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
11. The endothelin system: A new target for therapeutic intervention
12. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
13. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
14. Role of hemodynamics in pulmonary vascular remodeling: Implications for primary pulmonary hypertension
15. Primary pulmonary hypertension. Insights into pathogenesis from epidemiology
16. Clinical insights into the pathogenesis of primary pulmonary hypertension
17. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
18. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
19. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
20. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
21. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
22. Inhaled iloprost to treat severe pulmonary hypertension: An uncontrolled trial
23. Pulmonary hypertension: Diagnostics and therapeutics
24. Primary pulmonary hypertension: Natural history and the importance of thrombosis
25. High dose calcium channel-blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy
26. Calcium channel blockers in primary pulmonary hypertension
27. Verapamil and pulmonary hypertension
28. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease
29. The acute administration of vasodilators in primary pulmonary hypertension: Experience from the National Institutes of Health registry on primary pulmonary hypertension
30. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial
31. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
32. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion
33. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension
34. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers
35. Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future?
36. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
37. B receptors
38. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist
39. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
40. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
41. Bosentan therapy for pulmonary arterial hypertension
42. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication
43. Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure
44. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension
45. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension
46. Acute hemodynamic effects of subcutaneous UT 15 in primary pulmonary hypertension
47. Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension
48. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patient with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial
49. Efficacy of long-term subcutaneous infusion of UT-15 in primary pulmonary hypertension
50. Effect of beraprost sodium on peripheral circulation insufficiency in rats and rabbits
51. Medical therapy of pulmonary hypertension: The prostacyclins
52. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation
53. Orally active prostacyclin analogue in primary pulmonary hypertension